Clinical and microbiological features of providencia bacteremia: Experience at a tertiary care hospital

Korean Journal of Internal Medicine

Volumn 30, Issue 2, 2015, Pages 219-225

  Choi, Hee Kyoung ^a   Kim, Young Keun ^a   Kim, Hyo Youl ^a   Park, Jeong Eun ^a   Uh, Young ^a  

^a Yonsei University Wonju College of Medicine   (South Korea)

Author keywords

Bacteremia; Bacterial; Drug resistance; Mortality; Providencia

Indexed keywords

AMIKACIN; AMPICILLIN; AZTREONAM; CEFALOTIN; CEFAMANDOLE; CEFEPIME; CEFOPERAZONE PLUS SULBACTAM; CEFOTAXIME; CEFTAZIDIME; CIPROFLOXACIN; COTRIMOXAZOLE; GENTAMICIN; IMIPENEM; ISEPAMICIN; PIPERACILLIN PLUS TAZOBACTAM; TOBRAMYCIN; ANTIINFECTIVE AGENT;

ADOLESCENT; ADULT; AGED; ANTIBIOTIC SENSITIVITY; APACHE; ARTICLE; BACTEREMIA; BACTERIUM IDENTIFICATION; BACTERIUM ISOLATE; CATHETER INFECTION; CEREBROVASCULAR DISEASE; CHILD; CLINICAL ARTICLE; CLINICAL FEATURE; CROSS-SECTIONAL STUDY; DISEASE SEVERITY; FEMALE; HOSPITAL INFECTION; HUMAN; INCIDENCE; INDWELLING URINARY CATHETER; MALE; MEDICAL RECORD REVIEW; MORTALITY; NEUROLOGIC DISEASE; NONHUMAN; OUTCOME ASSESSMENT; PITT BACTEREMIA SCORE; POLYMICROBIAL BACTEREMIA; PROVIDENCIA; PROVIDENCIA ALCALIFACIENS; PROVIDENCIA BACTEREMIA; PROVIDENCIA RETTGERI; PROVIDENCIA STUARTII; SCORING SYSTEM; TERTIARY CARE CENTER; URINARY TRACT INFECTION; ANTIBIOTIC RESISTANCE; CROSS INFECTION; DRUG EFFECTS; ENTEROBACTERIACEAE INFECTIONS; HOSPITAL MORTALITY; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MIDDLE AGED; PREDICTIVE VALUE; RETROSPECTIVE STUDY; RISK FACTOR; SOUTH KOREA; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTI-BACTERIAL AGENTS; APACHE; BACTEREMIA; CHILD; CROSS INFECTION; CROSS-SECTIONAL STUDIES; DRUG RESISTANCE, BACTERIAL; ENTEROBACTERIACEAE INFECTIONS; FEMALE; HOSPITAL MORTALITY; HUMANS; INCIDENCE; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROVIDENCIA; REPUBLIC OF KOREA; RETROSPECTIVE STUDIES; RISK FACTORS; TERTIARY CARE CENTERS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84924405114     PISSN: 12263303     EISSN: 20056648     Source Type: Journal    
DOI: 10.3904/kjim.2015.30.2.219     Document Type: Article

References (22)

1. O’Hara CM, Brenner FW, Miller JM. Classification, identification, and clinical significance of Proteus, Providencia, and Morganella. Clin Microbiol Rev 2000;13:534-546.
2. Warren JW. Providencia stuartii: a common cause of antibiotic-resistant bacteriuria in patients with long-term indwelling catheters. Rev Infect Dis 1986;8:61-67.
3. Prentice B, Robinson BL. A review of Providencia bacteremia in a general hospital, with a comment on patterns of antimicrobial sensitivity and use. Can Med Assoc J 1979;121:745-749.
4. Woods TD, Watanakunakorn C. Bacteremia due to Providencia stuartii: review of 49 episodes. South Med J 1996;89:221-224.
5. Kim BN, Kim NJ, Kim MN, Kim YS, Woo JH, Ryu J. Bacteraemia due to tribe Proteeae: a review of 132 cases during a decade (1991-2000). Scand J Infect Dis 2003;35:98-103.
6. Stickler DJ. Susceptibility of antibiotic-resistant gram-negative bacteria to biocides: a perspective from the study of catheter biofilms. Symp Ser Soc Appl Microbiol 2002:163S-170S.
7. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing: 19th Informational Supplement. CLSI Document M100-S19. Wayne: Clinical and Laboratory Standards Institute, 2009.
8. Bone RC, Balk RA, Cerra FB, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis: the ACCP/SCCM Consensus Conference Committee: American College of Chest Physicians/ Society of Critical Care Medicine. Chest 1992;101:1644-1655.
9. McCabe WR, Jackson GG. Gram-negative bacteremia: II. clinical, laboratory, and therapeutic observations. Arch Intern Med 1962;110:856-864.
10. Chow JW, Yu VL. Combination antibiotic therapy versus monotherapy for gram-negative bacteraemia: a commentary. Int J Antimicrob Agents 1999;11:7-12.
11. Shima A, Hinenoya A, Asakura M, et al. Molecular characterizations of cytolethal distending toxin produced by Providencia alcalifaciens strains isolated from patients with diarrhea. Infect Immun 2012;80:1323-1332.
12. Albert MJ, Alam K, Ansaruzzaman M, et al. Pathogenesis of Providencia alcalifaciens-induced diarrhea. Infect Immun 1992;60:5017-5024.
13. Yoh M, Matsuyama J, Ohnishi M, et al. Importance of Providencia species as a major cause of travellers’ diarrhoea. J Med Microbiol 2005;54(Pt 11):1077-1082.
14. Kang CI, Song JH, Chung DR, et al. Risk factors and pathogenic significance of severe sepsis and septic shock in 2286 patients with gram-negative bacteremia. J Infect 2011;62:26-33.
15. Gikas A, Samonis G, Christidou A, et al. Gram-negative bacteremia in non-neutropenic patients: a 3-year review. Infection 1998;26:155-159.
16. Tumbarello M, Citton R, Spanu T, et al. ESBL-producing multidrug-resistant Providencia stuartii infections in a university hospital. J Antimicrob Chemother 2004;53:277-282.
17. Rose WE, Rybak MJ. Tigecycline: first of a new class of antimicrobial agents. Pharmacotherapy 2006;26:1099-1110.
18. Li J, Nation RL, Milne RW, Turnidge JD, Coulthard K. Evaluation of colistin as an agent against multi-resistant Gram-negative bacteria. Int J Antimicrob Agents 2005;25:11-25.
19. Fass RJ, Barnishan J, Ayers LW. Emergence of bacterial resistance to imipenem and ciprofloxacin in a university hospital. J Antimicrob Chemother 1995;36:343-353.
20. Robin F, Aggoune-Khinache N, Delmas J, Naim M, Bonnet R. Novel VIM metallo-beta-lactamase variant from clinical isolates of Enterobacteriaceae from Algeria. Antimicrob Agents Chemother 2010;54:466-470.
21. Shiroto K, Ishii Y, Kimura S, et al. Metallo-beta-lactamase IMP-1 in Providencia rettgeri from two different hospitals in Japan. J Med Microbiol 2005;54(Pt 11):1065-1070.
22. Zavascki AP, Carvalhaes CG, da Silva GL, et al. Outbreak of carbapenem-resistant Providencia stuartii in an intensive care unit. Infect Control Hosp Epidemiol 2012;33:627-630.